文献速递免疫规划传染病防控与疫情报告

四价登革疫苗与二价HPV疫苗在墨西哥9-14岁女孩中同时或序贯接种的免疫原性与安全性

Immunogenicity and safety of a tetravalent dengue vaccine and a bivalent HPV vaccine given concomitantly or sequentially in girls aged 9 to 14 years in Mexico.
PubMed 文献 · Vaccine · 2021-05-13

这项IIIb期随机开放多中心研究在墨西哥9-14岁女孩中比较四价登革疫苗(CYD-TDV)与二价HPV疫苗同时或序贯接种的免疫原性与安全性。基线登革血清阳性者中,同时组与序贯组HPV抗体滴度比值HPV-16为0.966、HPV-18为0.999,CYD-TDV第3剂后各血清型组间比值接近1,两组安全性相似。

要点

  • 基线登革血清阳性女孩中,同时接种与序贯接种的HPV抗体滴度相当。
  • CYD-TDV第3剂后各登革血清型抗体滴度组间比值接近1。
  • 两种接种程序安全性特征相似。

核心结论

  • 在9-14岁登革血清阳性女孩中,CYD-TDV与二价HPV疫苗同时或序贯接种产生相当的免疫应答且安全性相似。

研究设计与样本

  • IIIb期随机开放标签多中心研究(NCT02979535),在墨西哥9-14岁女孩中按1:1随机分组。
  • 受试者接受三剂CYD-TDV(间隔6个月)及两剂二价HPV疫苗,或与CYD-TDV前两剂同时接种,或提前1个月序贯接种。

主要发现

  • 随机参与者中305/478(63.8%)基线登革血清阳性:同时组154例,序贯组151例。
  • 末剂HPV疫苗后,血清阳性者HPV抗体滴度组间比值HPV-16为0.966、HPV-18为0.999。
  • CYD-TDV第3剂后各血清型抗体滴度组间比值接近1:血清型1为0.977、2为0.911、3为0.921、4为0.931。

临床怎么用

  • 对于9-14岁登革血清阳性女孩,可考虑同时或序贯接种CYD-TDV与二价HPV疫苗,免疫应答与安全性相似。

局限性

  • 免疫原性结果仅报告基线登革血清阳性参与者。
  • 研究为开放标签设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dengue is endemic in several regions, and the global incidence is increasing. The recombinant, live, attenuated, tetravalent dengue vaccine (CYD-TDV) is recommended for dengue seropositive individuals ≥ 9 years. Human papillomavirus (HPV) vaccination is recommended for girls aged 9-14 years to prevent HPV infection-related cancers. This study assessed the immunogenicity and safety of a bivalent HPV (types 16 and 18) vaccine and CYD-TDV when co-administered concomitantly or sequentially. This was a Phase IIIb, randomized, open-label, multicenter study in girls aged 9-14 years in Mexico (NCT02979535). Participants were randomized 1:1 to receive three doses of CYD-TDV 6 months apart and two doses of bivalent HPV vaccine either concomitantly with, or 1 month before (sequentially), the first 2 CYD-TDV doses. Antibody levels were measured at baseline and 28-days after each vaccine dose for all participants, using an enzyme-linked immunosorbent assay for HPV-16 and HPV-18 antibodies, and a plaque reduction neutralization test for the four dengue serotypes; results are reported only for participants who were seropositive at baseline. Safety was assessed for all randomized participants throughout the study. Of the randomized participants, 305/478 (63.8%) were seropositive for dengue at baseline: 154 in the concomitant group and 151 in the sequential group. After the last HPV vaccine dose, the antibody titers for HPV were comparable in seropositive participants between treatment groups, with between group titer ratios of 0.966 for HPV-16 and 0.999 for HPV-18. After dose 3 of CYD-TDV, antibody titers were comparable for the concomitant and sequential groups across all serotypes, with between-group ratios close to 1 (serotype 1: 0.977; serotype 2: 0.911; serotype 3: 0.921; serotype 4: 0.931). CYD-TDV and a bivalent HPV vaccine administered concomitantly or sequentially in dengue seropositive girls aged 9-14 years elicited comparable immune responses with similar safety profiles.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Arredondo JL, Villagomez Martinez SM, Concepcion Morales M, et al. Immunogenicity and safety of a tetravalent dengue vaccine and a bivalent HPV vaccine given concomitantly or sequentially in girls aged 9 to 14 years in Mexico. Vaccine. 2021. PMID: 33992441. doi:10.1016/j.vaccine.2021.04.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。